70 related articles for article (PubMed ID: 25491441)
1. The V600E BRAF mutation in a borderline serous tumour of the testis is genotypic evidence of similarity with its phenotypic ovarian counterpart.
Cundell D; Pawade J; Sohail M; Melegh Z
Histopathology; 2015 Jul; 67(1):142-4. PubMed ID: 25491441
[No Abstract] [Full Text] [Related]
2. Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis.
Bürger T; Schildhaus HU; Inniger R; Hansen J; Mayer P; Schweyer S; Radzun HJ; Ströbel P; Bremmer F
Diagn Pathol; 2015 Jul; 10():118. PubMed ID: 26197800
[TBL] [Abstract][Full Text] [Related]
3. The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series.
Gwiti P; Vereczkey I; Cundell D; Aslam S; Clench T; Csernák E; Götzer K; Braybrooke J; Sohail M; Melegh Z
Histopathology; 2017 Nov; 71(5):686-692. PubMed ID: 28543997
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
[TBL] [Abstract][Full Text] [Related]
5. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
[TBL] [Abstract][Full Text] [Related]
6. The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
Yousem SA; Nikiforova M; Nikiforov Y
Am J Surg Pathol; 2008 Sep; 32(9):1317-21. PubMed ID: 18636014
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E Mutations in Endometrial Adenocarcinoma.
He M; Breese V; Hang S; Zhang C; Xiong J; Jackson C
Diagn Mol Pathol; 2013 Mar; 22(1):35-40. PubMed ID: 23370429
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
9. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
Honecker F; Wermann H; Mayer F; Gillis AJ; Stoop H; van Gurp RJ; Oechsle K; Steyerberg E; Hartmann JT; Dinjens WN; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Clin Oncol; 2009 May; 27(13):2129-36. PubMed ID: 19289622
[TBL] [Abstract][Full Text] [Related]
11. [BRAF mutation in colorectal serrated lesions].
Zhou ZY; Han Y; Wang LP
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3411-4. PubMed ID: 19159571
[TBL] [Abstract][Full Text] [Related]
12. Histopathological and molecular features of late relapses in non-seminomas.
Mayer F; Wermann H; Albers P; Stoop H; Gillis AJ; Hartmann JT; Bokemeyer CC; Oosterhuis JW; Looijenga LH; Honecker F
BJU Int; 2011 Mar; 107(6):936-43. PubMed ID: 20955261
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
14. Serous papillary adenocarcinoma of the rete testis: unusual ultrasonography and pathological findings.
Mermershtain W; Vardi N; Gusakova I; Klein J
J Cancer Res Ther; 2007; 3(1):37-9. PubMed ID: 17998718
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
[TBL] [Abstract][Full Text] [Related]
16. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
Gautschi O; Pauli C; Strobel K; Hirschmann A; Printzen G; Aebi S; Diebold J
J Thorac Oncol; 2012 Oct; 7(10):e23-4. PubMed ID: 22743296
[No Abstract] [Full Text] [Related]
17. Intratesticular borderline serous tumor.
Abdullah LS; Gupta R; Arnst A
Int J Urol; 2006 Dec; 13(12):1536-8. PubMed ID: 17118032
[TBL] [Abstract][Full Text] [Related]
18. No evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody.
Preusser M; Berghoff AS; Capper D; von Deimling A; Maroske F; Brodowicz T; Hejna M; Birner P; Schoppmann SF
Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):426-30. PubMed ID: 23343956
[TBL] [Abstract][Full Text] [Related]
19. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
20. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
